EUVIMEDEUVIMED entdecken
Crossref

Development and Evaluation of Glimepiride Transdermal Patches for Sustained Drug Delivery

Voleti Vijaya Kumar, S. Vamsi Krishna, Naga Lakshmi Ponnada, K. Thamizhvanan, Joan Vijetha. R, S. Shyam Sudarsan, S. Ushna

International Journal of Drug Delivery Technology · 23.04.2026 · 16 (16s)

DOI: 10.25258/ijddt.16.16s.78 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 23.04.2026. Verfasst von Voleti Vijaya Kumar und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-term management of Type 2 diabetes mellitus often relies on oral hypoglycaemic agents such as glimepiride; however, conventional administration is associated with variable bioavailability, first-pass metabolism, and fluctuations in plasma drug levels. These limitations can affect therapeutic outcomes and patient adherence.

Objective

The present study was undertaken to develop and evaluate a membrane-moderated transdermal drug delivery system of glimepiride capable of providing controlled and sustained drug release.

Methods

Transdermal patches were fabricated using a solvent casting technique with HPMC K100M and Eudragit RLPO as rate-controlling polymers. The formulations were subjected to pre-formulation studies, drug–polymer compatibility analysis using DSC and FTIR, and evaluation of physicochemical and mechanical properties. In-vitro drug release studies and stability testing under ICH conditions were also performed.

Results

The prepared patches exhibited uniform thickness, satisfactory mechanical strength, and consistent drug content. Compatibility studies confirmed the stability of glimepiride within the polymeric system. In-vitro release profiles demonstrated sustained drug release over 24 hours, with the optimized formulation achieving near-complete release while maintaining controlled kinetics. Stability studies indicated no significant changes in physicochemical properties or drug release behaviour over the study period.

Conclusion

The developed transdermal system effectively provided controlled delivery of glimepiride and demonstrated adequate stability and performance characteristics. This approach offers a promising alternative to oral therapy by supporting sustained drug release and potentially improving therapeutic consistency in the management of Type 2 diabetes mellitus.

Zitieren

APA

Kumar, V. V., Krishna, S. V., Ponnada, N. L., Thamizhvanan, K., R, J. V., Sudarsan, S. S., & Ushna, S. (2026). Development and Evaluation of Glimepiride Transdermal Patches for Sustained Drug Delivery. International Journal of Drug Delivery Technology, 16(16s). https://doi.org/10.25258/ijddt.16.16s.78

Vancouver

Kumar VV, Krishna SV, Ponnada NL, Thamizhvanan K, R JV, Sudarsan SS, et al. Development and Evaluation of Glimepiride Transdermal Patches for Sustained Drug Delivery. International Journal of Drug Delivery Technology. 2026;16(16s). doi:10.25258/ijddt.16.16s.78

BibTeX
@article{Kumar2026,
  author = {Kumar, Voleti Vijaya and Krishna, S. Vamsi and Ponnada, Naga Lakshmi and Thamizhvanan, K. and R, Joan Vijetha. and Sudarsan, S. Shyam and Ushna, S.},
  title = {Development and Evaluation of Glimepiride Transdermal Patches for Sustained Drug Delivery},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {16s},
  doi = {10.25258/ijddt.16.16s.78}
}
Kostenlos starten →